公开(公告)号：KR1020090128223A

公开(公告)日：2009-12-15

申请号：KR1020080054286

申请日：2008-06-10

Applicant: 서울대학교산학협력단

Inventor： 정지형 ,  김동규 ,  유은숙 ,  당테흥 ,  강헌중

IPC: A61K31/201 ,  A61K31/20 ,  A61P35/00

Abstract: PURPOSE: A pharmaceutical composition for preventing and treating cancer containing enoic acid fatty acid as an active ingredient is provided to suppress cell growth and induce apoptosis so prevent and treat cancer. CONSTITUTION: A pharmaceutical composition for preventing and treating cancer contains enone compound of chemical formula 1 or 2 as an active ingredient. In chemical formulas 1 and 2, R is OH, alkoxy group of C1-C4, COOH, COOCH3, CH2OH or CH2NHCOCF3, and m and n is integer of 2 to 4, respectively. A health food for treating cancer contains a compound of chemical formula 1 or 2 as an active ingredient. The enoic acid fatty acid compound induces apoptosis and suppresses cell growth by DNA replication. The dose of the enoic acid fatty acid is 2~10 mg/kg once or several time a day.

Abstract translation: 目的：提供一种用于预防和治疗含有烯酸脂肪酸的癌症作为活性成分的药物组合物，以抑制细胞生长并诱导凋亡，从而预防和治疗癌症。 构成：用于预防和治疗癌症的药物组合物含有化学式1或2的烯酮化合物作为活性成分。 在化学式1和2中，R是OH，C 1 -C 4的烷氧基，COOH，COOCH 3，CH 2 OH或CH 2 NHCOCF 3，m和n分别是2至4的整数。 用于治疗癌症的保健食品含有化学式1或2的化合物作为活性成分。 烯酸脂肪酸化合物诱导凋亡并通过DNA复制抑制细胞生长。 烯酸脂肪酸的剂量为2〜10mg / kg，一次或几次。

公开(公告)号：KR101012313B1

公开(公告)日：2011-02-09

申请号：KR1020080054293

申请日：2008-06-10

Applicant: 서울대학교산학협력단

Inventor： 정지형 ,  유은숙 ,  당테흥 ,  강헌중

IPC: A61K31/201 ,  A61K31/075 ,  A61P29/00

Abstract: 본 발명은 하기 화학식 1로 표시되는 화합물을 유효성분으로 함유하는 염증질환 치료제에 관한 것으로, 이러한 화합물은 LPS로 활성화된 RAW 264.7세포에서 NO, IL-6 및 TNF-a와 같은 염증성 매개물의 생성을 억제함으로써 염증 질환의 치료제로서 유용하게 이용될 수 있다.
[화학식 1]

염증질환, NO, IL-6, TNF-α

公开(公告)号：KR1020090128229A

公开(公告)日：2009-12-15

申请号：KR1020080054293

申请日：2008-06-10

Applicant: 서울대학교산학협력단

Inventor： 정지형 ,  유은숙 ,  당테흥 ,  강헌중

IPC: A61K31/201 ,  A61K31/075 ,  A61P29/00

Abstract: PURPOSE: A therapeutic agent containing a compound as an active ingredient for treating inflammatory disease is provided to suppress generation of inflammatory media such as NO(nitrogen oxide), IL-6(interleukin-6) and TNF-α(tumor necrosis factor-alpha) in LPS-activated RAW 264.7 cell. CONSTITUTION: A therapeutic agent for treating inflammatory diseases contains a compound of the chemical formula 1 as an active ingredient. In chemical formula 1, R is COOH, COOCH3, CH2OH or CH2NHCOCF3, R1 and R2 is H, C6H5, or Br, and m is 1-5 integer and n is 1-4 integer. The compound of chemical formula 1 is (E)-11-oxooctadeca-9-enole, (E)-10- oxooctadeca-8-enole, (E)-9-oxooctadeca-10-enole or (E)-8-oxooctadeca-9-enole. The inflammatory diseases are rheumatoid arthritis, inflammatory bowel disease, osteoporosis, psoriasis, or toxic shock syndrome.

Abstract translation: 目的：提供含有化合物作为治疗炎性疾病的活性成分的治疗剂，以抑制炎症介质如NO（氮氧化物），IL-6（白细胞介素-6）和TNF-α（肿瘤坏死因子-α ）在LPS激活的RAW 264.7细胞中。 构成：用于治疗炎性疾病的治疗剂含有化学式1的化合物作为活性成分。 在化学式1中，R为COOH，COOCH3，CH2OH或CH2NHCOCF3，R1和R2为H，C6H5或Br，m为1-5整数，n为1-4整数。 化学式1的化合物是（E）-11-氧代十八碳-9-烯醇，（E）-10-氧代十八碳-8-烯醇，（E）-9-氧代十八碳-10-烯醇或（E）-8-氧代十八碳烯 -9- enole。 炎症性疾病是类风湿性关节炎，炎性肠病，骨质疏松症，牛皮癣或中毒性休克综合征。